A novel combination treatment against melanoma with NRAS mutation and therapy resistance

Targeted cancer therapies have shown some progress in treating BRAF‐mutant melanoma, but not against NRAS‐mutant and treatment‐resistant melanoma. In this issue of EMBO Molecular Medicine, Echevarría‐Vargas et al (2018) report that cotargeting BET and MEK pathways efficiently kills immune therapy‐re...

Descripción completa

Detalles Bibliográficos
Autor principal: Yu, Yanlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938621/
https://www.ncbi.nlm.nih.gov/pubmed/29661909
http://dx.doi.org/10.15252/emmm.201708573
_version_ 1783320817059233792
author Yu, Yanlin
author_facet Yu, Yanlin
author_sort Yu, Yanlin
collection PubMed
description Targeted cancer therapies have shown some progress in treating BRAF‐mutant melanoma, but not against NRAS‐mutant and treatment‐resistant melanoma. In this issue of EMBO Molecular Medicine, Echevarría‐Vargas et al (2018) report that cotargeting BET and MEK pathways efficiently kills immune therapy‐resistant and NRAS‐mutant melanoma tumor cells.
format Online
Article
Text
id pubmed-5938621
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59386212018-05-14 A novel combination treatment against melanoma with NRAS mutation and therapy resistance Yu, Yanlin EMBO Mol Med News & Views Targeted cancer therapies have shown some progress in treating BRAF‐mutant melanoma, but not against NRAS‐mutant and treatment‐resistant melanoma. In this issue of EMBO Molecular Medicine, Echevarría‐Vargas et al (2018) report that cotargeting BET and MEK pathways efficiently kills immune therapy‐resistant and NRAS‐mutant melanoma tumor cells. John Wiley and Sons Inc. 2018-04-16 2018-05 /pmc/articles/PMC5938621/ /pubmed/29661909 http://dx.doi.org/10.15252/emmm.201708573 Text en Published 2018. This article is a U.S. Government work and is in the public domain in the USA This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Views
Yu, Yanlin
A novel combination treatment against melanoma with NRAS mutation and therapy resistance
title A novel combination treatment against melanoma with NRAS mutation and therapy resistance
title_full A novel combination treatment against melanoma with NRAS mutation and therapy resistance
title_fullStr A novel combination treatment against melanoma with NRAS mutation and therapy resistance
title_full_unstemmed A novel combination treatment against melanoma with NRAS mutation and therapy resistance
title_short A novel combination treatment against melanoma with NRAS mutation and therapy resistance
title_sort novel combination treatment against melanoma with nras mutation and therapy resistance
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938621/
https://www.ncbi.nlm.nih.gov/pubmed/29661909
http://dx.doi.org/10.15252/emmm.201708573
work_keys_str_mv AT yuyanlin anovelcombinationtreatmentagainstmelanomawithnrasmutationandtherapyresistance
AT yuyanlin novelcombinationtreatmentagainstmelanomawithnrasmutationandtherapyresistance

Ejemplares similares